Literature DB >> 11085732

Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies.

S K Libutti1, D L Barlett, D L Fraker, H R Alexander.   

Abstract

BACKGROUND: For a variety of histologies, the liver represents the only or the dominant site of metastatic disease. Regional treatment of the liver has the theoretic advantage of maximizing drug delivery while minimizing systemic toxicity. This article describes the technique of isolated hepatic perfusion using tumor necrosis factor and melphalan under conditions of moderate hyperthermia for the treatment of unresectable liver tumors. STUDY
DESIGN: Fifty patients with biopsy-proved unresectable primary or metastatic cancer to the liver were treated. Isolated hepatic perfusion was performed for 60 minutes under conditions of moderate hyperthermia during a laparotomy with inflow through the gastroduodenal artery and outflow through an isolated segment of inferior vena cava. During isolated hepatic perfusion portal and infrahepatic blood flow were shunted externally by a centrifugal pump to the axillary vein. Complete vascular isolation was confirmed intraoperatively using a continuous 131I-labeled serum albumin leak monitoring system. Operative and perfusion parameters were recorded.
RESULTS: By using a standard operative technique to achieve complete vascular isolation of the liver during perfusion, there was no leak ofperfusate detected in 48 of 50 patients as determined by the continuous leak monitoring system and absence of detectable systemic tumor necrosis factor levels. Operating time, transfusion requirements, and blood loss were within the range expected for a major operative procedure. Stable hemodynamic and perfusion parameters were achieved consistently and all patients successfully completed the 60-minute perfusion. Two patients (4%) died as a result of treatment and significant tumor regression was observed in 75%.
CONCLUSIONS: Isolated hepatic perfusion is a technique that can be used to deliver high doses of chemotherapy or biologic therapy regionally and without systemic exposure. By using a standard operative technique, continuous intraoperative leak monitoring, and an external veno-veno bypass circuit, this procedure can be done safely and with acceptable morbidity and mortality. This article demonstrates that sustained and complete vascular isolation of the liver can be achieved and indicates further study is warranted to better define the role of isolated hepatic perfusion in the treatment of unresectable liver tumors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11085732     DOI: 10.1016/s1072-7515(00)00733-x

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  8 in total

1.  Percutaneous isolated liver perfusion with occlusion balloons and a catheter-based stent-graft-like perfusion device: an experimental study in a porcine model.

Authors:  Geert Maleux; Diethard Monbaliu; Chris Verslype; Christophe Casteleyn; Marc Van De Velde; Pieter Cornillie; Yvonne Hoogeveen; Eric Van Cutsem
Journal:  Eur Radiol       Date:  2010-05-22       Impact factor: 5.315

2.  Flushing out antibodies to make AAV gene therapy available to more patients.

Authors:  Steven E Raper; James M Wilson; Frederick A Nunes
Journal:  Mol Ther       Date:  2013-02       Impact factor: 11.454

3.  Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies.

Authors:  James F Pingpank; Steven K Libutti; Richard Chang; Bradford J Wood; Ziv Neeman; Anthony W Kam; William D Figg; Souping Zhai; Tatiana Beresneva; Geoffrey D Seidel; H Richard Alexander
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

4.  Transcriptional control of viral gene therapy by cisplatin.

Authors:  James O Park; Carlos A Lopez; Vinay K Gupta; Charles K Brown; Helena J Mauceri; Thomas E Darga; Abdullah Manan; Samuel Hellman; Mitchell C Posner; Donald W Kufe; Ralph R Weichselbaum
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

5.  Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion.

Authors:  Elizabeth D Feldman; Peter C Wu; Tatiana Beresneva; Cynthia Helsabeck; Montessa Rodriguez; David L Bartlett; Steven K Libutti; James F Pingpank; H Richard Alexander
Journal:  J Gastrointest Surg       Date:  2004-02       Impact factor: 3.452

6.  The effect of chemotherapy combined with recombination mutant human tumor necrosis factor on advanced cancer.

Authors:  Xing Liu; Xiang-Fu Zhang; Zhi-Weng Zheng; Huishan Lu; Xinyuan Wu; Changmin Huang; Chuan Wang; Guoxiang Guang
Journal:  J Transl Med       Date:  2004-10-14       Impact factor: 5.531

7.  Evidence for two modes of synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia in human colon cancer cells.

Authors:  Xinxin Song; Seog-Young Kim; Yong J Lee
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

8.  Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity.

Authors:  Z Yuan; G Syrkin; A Adem; R Geha; J Pastoriza; C Vrikshajanani; T Smith; T J Quinn; G Alemu; H Cho; C J Barrett; W Arap; R Pasqualini; S K Libutti
Journal:  Cancer Gene Ther       Date:  2012-11-16       Impact factor: 5.987

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.